Search

Sodium phosphate, monobasic, unspecified form

Allogeneic processed thymus tissue

[L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.

Cinacalcet

Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. … It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

Edotreotide gallium Ga-68

[A185852] Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.[A185852] Edotreotide gallium Ga-68 was granted FDA approval on 21 August 2019.[L8597] … [L8603] Edotreotide gallium Ga-68 is indicated for localizing somatostatin receptor positive neuroendocrine tumors by positron emission tomography.

Dextropropoxyphene

Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

Gestrinone

Without significant advantages over other oral contraceptives and with its high cost, gestrinone was no longer used after the Stage II clinical trials. … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and

Nabilone

It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. … Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA

Zopapogene imadenovec

[L54071] It is the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081] … Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory

Margetuximab

[A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … [A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986]

Barium sulfate

Barium sulfate is ingested by mouth or administered rectally and combined with granules of effervescent bicarbonate to enhance distension of the GI tract, allowing for enhanced gastrointestinal tract visualization … It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield [L1957]. This drug is used as a contrast agent in diagnostic x-ray procedures.